HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

Heart 2008;94:971-972; doi:10.1136/hrt.2008.144816
Copyright © 2008 BMJ Publishing Group Ltd & British Cardiovascular Society

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Voors, A. A
Right arrow Articles by de Jong, R. M
PubMed
Right arrow PubMed Citation
Right arrow Articles by Voors, A. A
Right arrow Articles by de Jong, R. M

EDITORIALS

Treating diastolic heart failure

Adriaan A Voors, Richard M de Jong

Department of Cardiology, University Medical Centre Groningen, Groningen, The Netherlands

Correspondence to:
Dr A A Voors, Department of Cardiology, University Medical Centre Groningen, Hanzeplein 1, PO Box 30.001, 9700 RB Groningen, The Netherlands; a.a.voors@thorax.umcg.nl

The first 150 words of the full text of this article appear below.

In around half of patients diagnosed with heart failure, a relatively preserved systolic function (left ventricular ejection fraction (LVEF) >0.40–0.50) is found. These patients are generally diagnosed with diastolic heart failure or heart failure with preserved ejection fraction. Owing to an ageing population and an increased incidence of hypertension and diabetes, this percentage is expected to increase in the near future.

The diagnosis of diastolic heart failure is challenging. In a consensus statement of the European Society of Cardiology, the definition of diastolic heart failure is based on signs and symptoms of heart failure, a relatively preserved left ventricular systolic function (LVEF >0.40–0.50), evidence of diastolic dysfunction on echocardiography and raised natriuretic peptides.1

Treatment of diastolic heart failure is hampered by the absence of evidence for a specific drug that can reduce mortality and morbidity in these patients. Theoretically, a number of treatments might benefit patients with diastolic heart failure. . . . [Full text of this article]







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2008 BMJ Publishing Group Ltd & British Cardiovascular Society